Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial

Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J, Bloch MJ, Daemen J, Lobo MD, Mahfoud F, Schmieder R, Sharp ASP, Weber MA, Sapoval M, Fong P, Pathak A, Lantelme P, Hsi D, Bangalore S, Witkowski A, Weil J, Kably B, Barman NC, Reeve-Stoffer H, Coleman L, Mcclure CK, Kirtane AJ (2021)


Publication Type: Journal article

Publication year: 2021

Journal

Book Volume: 397

Pages Range: 2476-2486

Journal Issue: 10293

DOI: 10.1016/S0140-6736(21)00788-1

Abstract

Background Endovascular renal denervation reduces blood pressure in patients with mild-to-moderate hypertension, but its efficacy in patients with true resistant hypertension has not been shown. We aimed to assess the efficacy and safety of endovascular ultrasound renal denervation in patients with hypertension resistant to three or more antihypertensive medications.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Azizi, M., Sanghvi, K., Saxena, M., Gosse, P., Reilly, J.P., Levy, T.,... Kirtane, A.J. (2021). Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. The Lancet, 397(10293), 2476-2486. https://doi.org/10.1016/S0140-6736(21)00788-1

MLA:

Azizi, Michel, et al. "Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial." The Lancet 397.10293 (2021): 2476-2486.

BibTeX: Download